Le Lézard
Classified in: Health
Subject: SVY

Intravenous (IV) Iron Drugs: The Global Market is Projected to Grow Tremendously During 2018-2022


DUBLIN, Nov. 15, 2018 /PRNewswire/ --

The "Global Intravenous (IV) Iron Drugs Market: Size, Trends and Forecasts (2018-2022)" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global intravenous (IV) iron drugs market has increased at a significant CAGR during the years 2013-2017 and projections are made that the market will rise in the next four years i.e. 2018-2022, tremendously.

The intravenous (IV) iron drugs market is expected to increase due to aging population, growing chronic diseases, escalating diabetic population, rising number of patients with chronic kidney disease, surge in the number of people with cancer, etc. Yet the market faces some challenges such as shift from Erythropoietin Stimulating Agents (ESAs) to HIF inhibitors, side effects associated with the use of intravenous iron drugs, etc.

The global intravenous (IV) iron drugs market is highly fragmented with many intravenous (IV) iron drugs market players operating worldwide. Some intravenous (IV) iron drugs market players operating on a local level while other players operating on a regional and global level. The manufacturers of intravenous (IV) iron drugs market produce intravenous iron drugs for different indications, with different iron content and in different doses.

However, the competition in the global intravenous (IV) iron drugs market is dominated by few intravenous iron drugs manufacturers. Further, key players of the intravenous (IV) iron drugs market are Vifor Pharma AG, Sanofi, AMAG Pharmaceuticals Inc., and Daiichi Sankyo Co. Ltd. are also profiled with their financial information and respective business strategies.

Key Topics Covered

1. Executive Summary

2. Introduction
2.1 Iron Supplements: An Analysis
2.1.1 Types of Iron Supplements
2.2 Intravenous Iron Drugs: An Analysis
2.2.1 Main Clinical Indications for Intravenous (IV) Iron Treatment
2.2.2 Reasons Favoring Intravenous Iron Use Over Oral Iron
2.2.3 Side Effects and Complications
2.3 Intravenous Iron Drugs Segmentation: An Overview
2.3.1 Intravenous Iron Drugs Segmentation by Product
2.3.2 Intravenous Iron Drugs Segmentation by Type
2.3.3 Intravenous Iron Drugs Segmentation by Indication

3. Global Market Analysis
3.1 Global Iron Drugs Market: An Analysis
3.1.1 Global Iron Drugs Market by Value
3.1.2 Global Iron Drugs Market by Segments (Oral Iron Drugs and Intravenous Iron Drugs)
3.1.3 Global Oral Iron Drugs Market by Value
3.2 Global Intravenous (IV) Iron Drugs Market: An Analysis
3.2.1 Global IV Iron Drugs Market by Value
3.2.2 Global IV Iron Drugs Market by Product (Injectafer/Ferinject, Venofer and Other Products)
3.2.3 Global IV Iron Drugs Market by Type (Ferric Carboxymaltose, Sucrose, Dextran and Others)
3.2.4 Global IV Iron Drugs Market by Region (The US, Europe and ROW)
3.3 Global Intravenous (IV) Iron Drugs Market: Product Analysis
3.3.1 Global Injectafer/Ferinject IV Iron Drugs Market by Value
3.3.2 Global Venofer IV Iron Drugs Market by Value
3.3.3 Global Other IV Iron Drugs Market by Value
3.4 Global Intravenous (IV) Iron Drugs Market: Type Analysis
3.4.1 Global Ferric Carboxymaltose IV Iron Drugs Market by Value
3.4.2 Global Sucrose IV Iron Drugs Market by Value
3.4.3 Global Dextran IV Iron Drugs Market by Value

4. Regional Market Analysis
4.1 The US Intravenous (IV) Iron Drugs Market: An Analysis
4.1.1 The US IV Iron Drugs Market by Value
4.1.2 The US IV Iron Drugs Market by Products (Venofer, Injectafer and Other Products)
4.1.3 The US IV Iron Drugs Market by Indication (Chronic Kidney Disease, Iron Deficiency Anemia, Inflammatory Bowel Disease, Oncology and Heart Failure)
4.2 The US Intravenous (IV) Iron Drugs Market: Product Analysis
4.2.1 The US Injectafer IV Iron Drugs Market by Value
4.2.2 The US Injectafer IV Iron Drugs Market by Indication (Iron Deficiency Anemia, Inflammatory Bowel Disease, Oncology, Chronic Kidney Disease, Heart Failure and Other)
4.2.3 The US Iron Deficiency Anemia (IDA) Injectafer IV Iron Drugs Market by Value
4.2.4 The US Inflammatory Bowel Disease (IBD) Injectafer IV Iron Drugs Market by Value
4.2.5 The US Oncology Injectafer IV Iron Drugs Market by Value
4.2.6 The US Chronic Kidney Disease (CKD) Injectafer IV Iron Drugs Market by Value
4.2.7 The US Heart Failure Injectafer IV Iron Drugs Market by Value
4.2.8 The US Other Injectafer IV Iron Drugs Market by Value
4.2.9 The US Venofer IV Iron Drugs Market by Value
4.2.10 The US Other IV Iron Drugs Market by Value
4.3 The US Intravenous (IV) Iron Drugs Market: Indication Analysis
4.3.1 The US Iron Deficiency Anemia (IDA) IV Iron Drugs Market by Value
4.3.2 The US Inflammatory Bowel Disease (IBD) IV Iron Drugs Market by Value
4.3.3 The US Oncology IV Iron Drugs Market by Value
4.3.4 The US Chronic Kidney Disease (CKD) IV Iron Drugs Market by Value
4.3.5 The US Heart Failure IV Iron Drugs Market by Value
4.4 Europe Intravenous (IV) Iron Drugs Market: An Analysis
4.4.1 Europe IV Iron Drugs Market by Value

5. Market Dynamics
5.1 Growth Driver
5.1.1 Rising Disposable Income
5.1.2 Aging Population
5.1.3 Growing Chronic Diseases
5.1.4 Escalating Diabetic Population
5.1.5 Increasing Prevalence of Anemia among Pregnant Women
5.1.6 Soaring Number of Patients with Chronic Kidney Disease (CKD)
5.1.7 Increasing Number of Patients with End-Stage-Renal-Disease (ESRD)
5.1.8 Surge in the Number of People with Cancer
5.2 Challenges
5.2.1 Shift from Erythropoietin Stimulating Agents (ESAs) to HIF Inhibitors
5.2.2 Side Effects Associated with the Use of Intravenous Iron Drugs
5.3 Market Trends
5.3.1 Increasing Healthcare Expenditure in Emerging Economies
5.3.2 Increasing Use of Intravenous Iron Drugs over Oral Iron Drugs
5.3.3 Emerging Second and Third Generation Intravenous Iron Drugs
5.3.4 Evolution of Combination Products

6. Competitive Landscape
6.1 Global Intravenous (IV) Iron Drugs Market Players: A Financial Comparison
6.2 Global Intravenous (IV) Iron Drugs Market Players: Product Comparison
6.3 Global Intravenous (IV) Iron Drugs Market Players by FDA Drug Approval

7. Company Profiles
7.1 Vifor Pharma AG
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 Sanofi
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 AMAG Pharmaceuticals Inc.
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
7.4 Daiichi Sankyo Co. Ltd.
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy

For more information about this report visit https://www.researchandmarkets.com/research/8qvhcd/intravenous_iv?w=5

Media Contact:

Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 05:00
The "Immunoassay Markets. Strategies and Trends. Forecasts by Application, Technology, Product, User and by Country. With Executive Guides, Customized Forecasting and Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering....

at 05:00
Medical equipment manufacturing company Aohua Endoscopy clinched the Endoscopy Product Innovation Award at the recently held Healthcare Asia Medtech Awards 2024 for its development of the Aohua 4K AQ-300 video endoscopy system, which offers an...

at 03:52
The progressive decrease in hearing in elderly people can represent a major problem for their quality of life: it has in fact been demonstrated that critical issues such as these, in addition to being a problem as such, can...

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...



News published on and distributed by: